Background: Donepezil hydrochloride (CAS 120014-06-4) isapiperidine-based, reversible inhibitorof the enzyme acetylcholinesterase( AChE). Itispostulated to exert its therapeuticeffectbyenhancing cholinergicfunction. Thisisaccomplished byincreasing the concentration of acetylcholine (ACh) through reversible inhibition of its hydrolysisbyAChE.
Background: Donepezil hydrochloride (CAS 120014-06-4) isapiperidine-based, reversible inhibitorof the enzyme acetylcholinesterase( AChE). Itispostulated to exert its therapeuticeffectbyenhancing cholinergicfunction. Thisisaccomplished byincreasing the concentration of acetylcholine (ACh) through reversible inhibition of its hydrolysisbyAChE.
Objective: The aim of thiss tudyw asto assess the bioequivalenceo fanewdonepezil 10mg formulation (test formulation) vs.the referencep roduct,a sr equired byEuropeanregulatory authoritiesfort he marketing of ageneric product.Additionally,the applicability of the truncated areaundert he plasma concentration curve( AUC)approachto thisdrugand undert hesetest conditions wasdetermined.
Methods: Thisw asasingle center,randomized,single-dose,open-label,2-way crossovers tudyin healthyv olunteers underfasting conditions.Plasmasamples werecollected upto288 hpost-dosing and (+)-donepezil and (-)-donepezil plasmalevelsw ered etermined byr everse liquid chromatographyand byt andem mass spectrometry detection (ie,the LC-MS/MS method). Pharmacokinetic parameters werecalculated using noncompartmentalanalysis.Areaundert he concentration-time curvef rom time zero tothe time of the last non-zeroconcentration (AUC last )and maximumo bserved concentration (C max )werethe main evaluation criteria, while areaundert he concentration-time curvefrom time zeroto infinity (AUC inf )wasalsoanalyzed foradditionali nformation. Fort he assessment of the applicability of the truncated AUC approach,A UCst runcated at2 4, 48, 72, 96, 144, 192 ,240,a nd 288 hwerecalculated. All of the abovementioned pharmacokineticparameters wereanalyzed using 90%geometricc onfidencei nterval of the ratio (T/R)o fl east-squaresmeans from the ANOVA of the ln-transformed parameter.Tolerability wasmonitored using physicale xamination,including vitalsign measurements and laboratory analysis.
Results: According tothe classical approach,the 90%geometricc onfidence intervalsobtained byanalysisof variance forAUC last ,C max and AUC inf werewithin the predefined ranges(80.00 -125.00 %) forbothanalytes.Truncated AUCsw ere alsoi nall casesw ithin the predefined rangesforacceptanceo fbioequivalence.
Conclusion: Bioequivalencebetween test and referencef ormulations,b othin termsof rateand extension of absorption, underfasting conditions,wasconcluded according toEuropeang uidelines.Both formulationswerewell tolerated.The conclusion of bioequivalencewasalso supported using the truncated AUCsapproach.
Introduction
Donepezil hydrochloride (CAS 120014-06-4) isapiperidine-based,reversible inhibitorof the enzyme acetylcholinesterase( AChE). Itispostulated toexert its therapeuticeffectbyenhancing cholinergicfunction. Thisis accomplished byincreasing the concentration of acetylcholine (ACh) through reversible inhibition of its hydrolysisbyAChE.Ifthisproposed mechanismo faction is correct,effectof donepezil maylessen ast he disease process advancesand fewercholinergicneuronsremain functionallyintact [1, 2] . Donepezil isindicated forthe symptomatictreatment of patients withm ild tom oderated ementiaof the Alzheimer'st ype. The usuald ailydosage is5to10mg. Adversee vents associated withd onepezil arel isted in the productmonograph [1, 2] . Donepezil isw ell absorbed witharelativeo ralbioavailability of 100 %. Afteroraladministration of asingle oraldoseof10mg donepezil (film-coated tablets)under fasting conditions,the maximumo bserved concentration (C max )i sr eached at2 .4 to4 .4 h( T max ) [3] [4] [5] [6] [7] .Pharmacokineticsarel inearoveradoserange of 1-10mg given onced aily.Neitherfood nort ime of administration (morning vs.e vening dose) influencest he rateo r extentof absorption of donepezil film-coated tablets [1, 2] .The elimination half life of donepezil isabout 70 h [1] and canthus beconsidered along half-life drug. Sex, raceand smoking history haven oclinicallys ignificant influenceo np lasmac oncentrationsof donepezil [2] . Donepezil isextensivelymetabolised and isalsoe xcreted in the urine asparentdrug. The rateo fm etabolismo fd onepezil isslowand doesnotappeartobesaturable. Donepezil ismetabolised byCYP450iso-enzymes2 D6and 3A4and undergoesglucuronidation. Donepezil isprimarilymetabolised byCYP450isoen-zymes2 D6and 3A4and undergoesfirst-pass metabolism [4, 8] .Thereare4majormetabolites,2of which areknowntobeactive. 6-O-desmethyldonepezil,which hassimilaractivity tothatof the parentcompound,was found in plasmaa tconcentrationsequaltoabout 20 % of donepezil [8] .Donepezil and its metabolitesarep rimarilyeliminated byr enale xcretion in humans [4, 8] . Approximately57%ofthe totaladministered radioactivity isr ecovered from the urine and 15 %i sr ecovered from the feces(totalrecovery of 72 %) overaperiod of 10days [1, 2] .
According tothe currentlyeffectiveEuropeang uideline [9] the biologicalsampling schedule should cover the concentration vs.time curvelong enough toprovide areliable estimateo fthe extentof absorption,which would beg enerallyachieved bycovering atleast 80.00 %ofthe totalareaunderthe curve. However,truncation of AUCsmaybeused asastrategytoshorten the lengtho fblood sample collection,especiallyin the case of drugsw ithalong half-life. Inthesecases,the total collection time should bej ustified and sample collection should ensureanadequatecomparison of the absorption phase [11] .
The presents tudyaimed tocomparethe relativebioavailability of anewdonepezil 10mg formulation manufactured byGrupo Tecnimede (Sintra, Portugal) and thatof areferencef ormulation sothatbioequivalence could beassessed,a sr equired byt he Europeanregulatory authoritiesfort he marketing of agenericproduct.
Additionally,the results obtained byt he truncated areaundert he curve( AUC)approachwereo btained and conclusionscompared tothoseo btained byt he conventionalapproach.
2.Subjects and methods

Studyprotocol
Ani ndependentethicscommittee,I nstitutionalReviewBoard Services,Ontario,C anada, approved the clinicalstudyprotocol and aletterof no-objection wasobtained from the Canadian authorities.The studyw asperformedi naccordancewiththe Helsinki Declaration and Good ClinicalPracticeGuideline [10] and ani nformed consentfrom participants wasobtained beforeanys tudyr elated procedurescommenced.The clinical part of the studyw asconducted att he AnapharmClinicalResearchFacility (Montréal,Q uébec, Canada)and the bioanalyticalpart atAnapharmEurope,SLfacility (Barcelona, Spain).
2.2Subjects
Subjects enrolled in thiss tudyw erem embers of the community atlarge. Subjects creening proceduresincluded informed consent,inclusion/exclusion check,demography,medicalh istory,medication history,physicale xamination,height,weight, bodymass index,aconcomitantmedication check,vitalsigns measurements (blood pressure,pulserate,respiratory rate, and oraltemperature),a12-leade lectrocardiogram( ECG),a urine drugscreen,aurine pregnancyt est (female subjects), hematology,b iochemistry,urinalysis,a nd HumanImmunodeficiencyVirus (HIV)and hepatitisBa nd Ctesting. All participating subjects werej udged eligible fort he studyw hen assessed against the inclusion and exclusioncriteria.
Subjects werem ale orfemale,lights mokerornon-smoker, ‡ 18 and £ 55 years of age,capable of consentwithabodymass index(BMI) ‡ 20.0and <25.0kg/m 2 .
Tolerability wasmonitored using physicale xamination (including vitalsign measurements)and ECG performed at screening and laboratory analysisincludingbiochemistry tests, hematologyt ests,a nd urinalysis,whichwerep erformedat screening and during the studyconduct.
Clinicall aboratory tests (hematology,b iochemistry,a nd urinalysis)werep erformed foreachsubjectatt he time of the screening and post-studyprocedures.Laboratory tests performed included the following:H ematology:c ompleteblood countw ithd ifferential,hemoglobin,hematocrit; Biochemistry: albumin,alkaline phosphatase,alanine aminotransferase(ALT/ SGPT),aspartateaminotransferase(AST/SGOT),ureanitrogen, calcium,c hloride,glucose,phosphorus,potassium,c reatinine, sodium,totalbilirubin,totalp rotein;Urinalysis:macroscopic examination,pH, specificgravity,protein,glucose,ketones,b ilirubin,occultblood and cells,nitrite,urobilinogen,leukocytes, microscopicexamination (performed on abnormalfindingsunless otherwisespecified). Electrocardiogramsand physicale xaminationsw ereperformed att he time of screeningo nly.
Vitalsignsmeasurements (blood pressure,heart rate,respiratory rate,a nd oraltemperature) werep erformedatt he time of screening,a nd post-studyprocedures.Inaddition, seated blood pressureand heart ratem easurements werep erformed priort od osing and approximately2 ,4,8,a nd 24h post-dose,in eachp eriod. Vitalsignsmeasurements wererepeated atleast onceass oon aspossible aftert he initialscheduled measurementu ndert he following conditions:systolic blood pressurem easurementlowert han9 0mmHgo rhigher than140mmHg,diastolicblood pressuremeasurement.
Subjects wereconfined tothe AnapharmClinicalResearch Facility from atleast 10hp riort od rugadministration until aftert he 24-h post-doseblood draw,in eachp eriod. The treatmentphaseswereseparated byawashout period of 35days. 
2.3Drugp roducts
Studydesign
Thisw asasingle centre,randomized,single-dose,open-label, 2-waycrossoverbioequivalencestudyt ocomparethe rateand extentof absorptiono ftest donepezil versus areferenced onepezil,underfasting conditions.Priort ostudycommencement, subjects wererandomlyassigned toatreatmentin accordance withthe computergenerated blockrandomization scheme (blocksize=4,randomlyvariable) generated byAnapharm.
Afterasupervised overnightfast of atleast 10h,the subjects wereadministered the test orr eferencem edication asasingle oraldoseof1film-coated tabletcontaining 10mg of donepezil with240mLof water.Subjects wered osed ass pecified in the protocol and subsequentlyfasted foraperiod of atleast 4h.
Blood sampleswerecollected priortostudydrugadministration and at0.50,1.00,1.50,2.00,2.50,3.00 
Randomization and blinding
The randomization scheme wasgenerated using SAS Ò program version 8.2(SAS InstituteInc.,C ary,N C, USA),performedbya biostatistician. The computer-generated sequencee nsured equald istribution of treatments.Aftert he random definition of the starting valueblocksof 10w ereg enerated from the list of the subjects'assignments. The subjects weree nrolled byaqualifiedi nvestigator.When arriving atthe clinicalfacility forthe first confinement,subjects wereassigned numbers,whichcorrespondedtoapreviously generated randomization scheme.
Volunteers wereadministered the test orr eferencem edication asperthe randomization scheme whichwaskeptunavailable tothe BioanalyticalDivision of AnapharmEurope S.L.until completiono fthe clinicaland analyticalp hases.The investigatorand clinicalstaff wereblinded toe achsubject's treatmentuntil afters ubjects qualified aseligible fort he study. The pharmacist who prepared the treatmentpers ubjectin accordancewiththe predetermined randomization planwasnot blinded tothe randomization scheme,but keptno contactwith the conductof the study.
2.6Druganalysis
All blood samplesw ered rawni ntoblood collection tubes (1 ×2mL)containing sodium-heparin,priort od rugadminis- The validation scheme involved the analysisof calibration curvesand quality controlsatdifferentconcentrationstodetermine linearity,within-runand between-runp recision and accuracy,limitof quantification,dilution factor,selectivity,recovery and stability.The analyticalp hasewasperformed in compliancewithGood Laboratory Practices(GLP).
2.7Pharmacokinetica nalysis
The mean,standardd eviation,c oefficientof variation and range forAUC last ,A UCinf,C max ,residualarea, T max ,T 1/2 and K el pharmacokineticparameters werecalculated from plasma concentrationsof (-)-donepezil and (+)-donepezil using a non-compartmentalm ethod. Truncated AUCsatt imesgreater thano requalto24h wereo btained byt he lineart rapezoidal method.
Pharmacokineticcalculationsweremade using Bioequiv(release3.50),aproprietary softwared eveloped and tested for bioequivalencestudiesatAnapharm,whichp erformsnoncompartmentalanalysesof pharmacokineticparameters and statisticalanalyses(viaSAS release8.2,S AS InstituteInc.,Cary, NC, USA),a nd alsousing WinNonLin (5.2.1,P harsight,M ountain View,C A, USA)fortruncated AUCs.
Statisticalanalysis
ANOVA wasperformedo nl n-transformed AUC last ,A UCinf and C max and untransformed K el and T 1/2 el atanalphalevel of 0.05. All ANOVAsw erep erformed withthe SAS (release8 .2forWin-dows)GeneralLinearModelsProcedureand Bioequiv(proprietary softwareversion 3.50). The model included sequence,sub-
CNS-activeDrugs·Hypnotics·Psychotropics·Sedatives
Arzneimittelforschung 2010;60(3):116-123 jectw ithin sequence,period and treatmentasfactors.The sequencee ffectw ast ested using subjects within sequencee ffect ast he errort erm. The treatmentand period effects weretested against the residualm eansquaree rror.All sumsof squares (TypesI, II, III and IV)werereported. Probability (p) values wered erived from Type III sumsof squares.Truncated AUCs wereanalyzed using WinNonLin (version 5.2.1,Pharsight)using asimilarstatisticalprocedure.
Forall analyses,effects wereconsidered statisticallys ignificantif the probability associated with' F'wasless than0.05. Based on pairwisecomparisonsof the ln-transformed AUC last , AUC inf and C max data, the ratiosof the least-squaresmeans,calculated according tothe formula"e (X-Y)×100",a sw ell ast he 90%g eometricC Iforln-transformedAUC last ,A UC inf ,C max and truncated AUCswered etermined.
3.Results
Druganalysis
Results obtained during the validation of the analytical method demonstrated its suitability fort he determination of (+)-donepezil and (-)-donepezil in humansodiumh eparinized plasmaa nd its application toclinical studies.
The lowerlimitof quantitation (LLOQ),i. e. the lowest standardl evel withac oefficientof variation less than 20 %,wass etat99.40pg/mLwithac oefficientof variation of 9.37 %and apercentage of nominalconcentration of 86.70 %f or(+)-donepezil and at49.80pg/mL withacoefficientof variation of 3. Analysisof drugconcentrationsw asperformed by AnapharmEurope (Barcelona, Spain),a ccording toGLP standards.Method used fort he analysiss howed good precision,a ccuracyand sensitivity and wass uitable for the determination of (+)-donepezil and (-)-donepezil in humanp lasmasamples.
3.2Subjects
Nineteen (9 femalesand (Fig. 1) . Baseline subjectcharacteristicsarep resented in Table 1 . 
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3.3Pharmacokinetica nd bioequivalenceanalysis
Meanp lasmac oncentrationsfor(+)-donepezil and (-)-donepezil arep resented in Fig. 2and Fig. 3 zil and (-)-donepezil forbothformulationsand analytes. The least-squaresmeansratiosand the 90%CIsarepre-sented in Table 3 .Forbothanalytes,AUC last ,AUC inf and C max 90%CIswerewithin 80.00 %and 125.00 %.
Fortruncated AUCs (Table 3) ,all of the 90%CIswere alsowithin the acceptancerange of 80.00 -125.00 %irre-spectiveo fthe period of time.
Tolerability analysis
Twenty-seven adversee vents (AEs)werereported by9 of the 19 subjects who received atleast one doseo fthe studymedication (safety population). The AEsdistribution bytreatmentgroupwasasfollows:12AEsreported by3 1.6%( n=6)o fthe 19 subjects who received treatmentA, 15 AEsr eported by3 8.9 %( n=7)o fthe 18 subjects who received treatmentB.The most commonlyreported AEsw ere" Post-proceduralswelling" reported by 21.1 %( n=4) of subjects who constituted the safety population and "Proceduralp ain" and "Headache" reported eachby10.5 %( n=2)o fsubjects." Post proceduralswelling" and "Proceduralp ain" wererelated to the studyproceduresand thereforen otexpected tobe associated withthe studymedication. "Headache" was expected following the administration of the medication and bothAEsw erej udged tobep ossiblyand unlikely related tothe medication. The remaining AEsr eported during the studyw erereported byasingle subjectfor eachAE.All AEsr eported wereg raded asmild. Ofthe 27 AEsreported,15 werej udged as"possible" and 12as "unlikely";t he expectedness of 14 AEsw asjudged as "expected" and 13as"notexpected". Noserious ors evereadversee vents werereported during thiss tudy. Upon conclusion of the clinicalp ortion of the study, the results from the subjects who completed post study procedures,including laboratory tests and vitalsigns measurements,c onfirmed the absenceo fsignificant changesin the subjects'stateo fh ealth. MedDRA classification of AEsand incidencearep resented in Table 4 . 
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Discussion
Bioequivalencestudiesareg eneralrequirements fort he registration of genericproducts.Arandomized crossoverdesign istypicallyemployed in bioequivalencestudies,a nd wasconsidered tobethe most appropriatef or thiss tudy.The studyw asopen-label in nature,b ecause blood concentration levelscann otbei nfluenced by knowledge of the identity of the treatment.The sampling schedule wasadequatei nthe characterization of bothe nantiomers'absorption phase,determination of AUC and C max parameters,a nd sufficientin the assessmentof the enantiomers' elimination phase,a st he 288 hsampling period covered asufficientperiod of time toallowt he characterization of the elimination phaseascanbeseen byt he lowr esidualarea. Even though plasmaconcentrationsof donepezil after oraldosing aredose-proportionalbetween 1and 10mg, therei sno evidenceo fd osel inearity foreache nantiomers taken separately.Therefore,achiralassaywasperformed toanalyze( +)-donepezil and (-)-donepezil in plasmasamples.
The meanresidualareawasless than20 %f orall treatments indicating thatasampling overaperiod of 288 hwass ufficientforboth( +)-donepezil and (-)-donepezil. Awashout period of atleast 35d ays thatr epresents morethan1 0t imest he half-life of donepezil was chosen toallowt he completee limination of the drug between the twoperiodsand toavoid carry-overeffects.
The results obtained using the truncated AUC approachwereinfull agreementwiththoseobtained using the classicalapproachwithout truncation. The new guideline [11] suggests thatasampling period longer than72 hisnotconsidered necessary foranyimmediate releasef ormulation. Hence,fordrugsw ithalong halflife,c omparison of extentof exposureusing truncated AUCsat7 2hi sacceptable. Given the physiological characteristicsof the absorption and the results obtained in thisstudy,truncation at7 2hseemstobeade-quateforthe determination of bioequivalencefordonepezil.
Bioequivalenceo fthe formulationsw ass hownast he 90%CIsof the ratio of least-squaresmeansof the test to referencep roductof ln-transformed AUC last and C max werewithin the acceptancerange of 80.00 %to 125.00 %f or(+)-donepezil and (-)-donepezil,following administration of a10mg film-coated tabletu nderfasting conditions.
Conclusion
Overall,the studydesign wasadequatetod etectdifferencesbetween the test and referencef ormulationsof donepezil hydrochloride underfasting conditions.Bioequivalencebetween formulations,in termsof rateand extentof absorption,wastherefored emonstrated.
Bothf ormulationsw erewell tolerated,withn orelevantdifferencesin safety profiles,particularlyw ithrespectt othe numberand characteristicsof adverse events.
Truncation of AUC at7 2hwass howntol eadtothe same conclusionsr egarding bioequivalenceo fd onepezil undert hesetest conditions.
Conflictof Interest
Thisr esearchwass ponsored byTecnimede,S ociedade Técni-co-MedicinalSA and authors areeitheremployeesof the sponsor(Tecnimede) orof ContractResearchOrganizations(Anapharmand AnapharmEurope). Earand labyrinthdisorders 1(1.5 %) Eardiscomfort 1(1.5 %) Eyed isorders 1(1.5 %) Conjunctivitis1(1.5 %) Gastrointestinald isorders 3(4.5 %) Abdominalp ain 1(1.5 %) Diarrhoea1(1.5 %) Nausea1(1.5 %) Toothache 1(1.5 %) Generald isorders and administration siteconditions 2(3.0%) Asthenia2(3.0%) Infectionsand infestations 1(1.5 %) 1( 1.4 %) Oralherpes1( 1.4 %) Rhinitis1(1.5 %) Injury,poisoning and procedural complications 3(4.5 %) 2(2.9 %) Post proceduralcomplication1 (1.5 %) Procedurald izziness 1(1.5 %) 2(2.9 %) Proceduralp ain 1(1.5 %) 1( 1.4 %) Investigations 9(13.6%) 9( 12.9 %) Blood pressured ecreased 6(9.1 %) 5( 7.1 %) Blood pressurei ncreased 1(1.5 %) Haematocritdecreased 1(1.5 %) 1( 1.4 %) Heart rated ecreased 1(1. 
CNS-activeDrugs·Hypnotics·Psychotropics·Sedatives
Forprivateorinternal corporateuseonly
